Rheumatoid arthritis prevalence in the us

Estimates and studies show that rheumatoid arthritis plagues 0·5–1·0% of adults in developed countries.Racial and ethnic differences may also play a role. Median time to first anti-TNF prescription was 6 months; 31% switched to a second drug and 15% to a third.Due to its severely debilitating nature, especially in advanced stages, the disease burden is considerable in economic and health expenditure terms. (2015), Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population. doi: 10.1002/acr.22646Incident and prevalent RA cohorts were defined from a sample of 4.66 million adults with complete followup data from the period of January 2005 through September 2008 in the Pharmetrics medical claims database. Demographics, comorbidity, and medical therapies were summarized using descriptive statistics. Within 12 months after diagnosis, 65%, 64%, and 20% of the incident cohort had been prescribed corticosteroids, nonbiologic disease-modifying antirheumatic drugs (DMARDs), and tumor necrosis factor (TNF) inhibitors, respectively.In USA the average age of persons with rheumatoid arthritis is 66.8 years. In this insured population-based cohort, only two-thirds of newly diagnosed RA patients were prescribed a DMARD in year 1 and 28% received no antirheumatic therapy.

While prevalence is 5-6% in some Native American groups, those hailing from the Caribbean region have lower prevalence rates.The rates of rheumatoid arthritis are more common among persons aged between 40 and 65 years. An aggressive subcohort (11% of incident patients) received more DMARDs (83%) and TNF inhibitors (43%), and was more likely to switch.However, this debilitating disease may affect persons at any age.While those living in northern Europe and North America are more prone to suffer from rheumatoid arthritis, those living in poorer and developing regions like rural West Africa are much less likely to develop rheumatoid arthritis.


Kommentar